JP6951976B2 - 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 - Google Patents

神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 Download PDF

Info

Publication number
JP6951976B2
JP6951976B2 JP2017539363A JP2017539363A JP6951976B2 JP 6951976 B2 JP6951976 B2 JP 6951976B2 JP 2017539363 A JP2017539363 A JP 2017539363A JP 2017539363 A JP2017539363 A JP 2017539363A JP 6951976 B2 JP6951976 B2 JP 6951976B2
Authority
JP
Japan
Prior art keywords
disease
effective dose
body weight
treat
alleviate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502898A (ja
JP2018502898A5 (enExample
Inventor
ロバート アロンソ，
ロバート アロンソ，
ジョン ジェラード ガイスラー，
ジョン ジェラード ガイスラー，
Original Assignee
マイトコン ファーマシューティカルズ， インコーポレイテッド
マイトコン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイトコン ファーマシューティカルズ， インコーポレイテッド, マイトコン ファーマシューティカルズ， インコーポレイテッド filed Critical マイトコン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018502898A publication Critical patent/JP2018502898A/ja
Publication of JP2018502898A5 publication Critical patent/JP2018502898A5/ja
Priority to JP2021031635A priority Critical patent/JP7440092B2/ja
Application granted granted Critical
Publication of JP6951976B2 publication Critical patent/JP6951976B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2017539363A 2015-01-22 2016-01-21 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 Active JP6951976B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021031635A JP7440092B2 (ja) 2015-01-22 2021-03-01 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106365P 2015-01-22 2015-01-22
US62/106,365 2015-01-22
PCT/US2016/014312 WO2016118741A1 (en) 2015-01-22 2016-01-21 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021031635A Division JP7440092B2 (ja) 2015-01-22 2021-03-01 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現

Publications (3)

Publication Number Publication Date
JP2018502898A JP2018502898A (ja) 2018-02-01
JP2018502898A5 JP2018502898A5 (enExample) 2019-02-28
JP6951976B2 true JP6951976B2 (ja) 2021-10-20

Family

ID=55310938

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017539363A Active JP6951976B2 (ja) 2015-01-22 2016-01-21 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP2021031635A Active JP7440092B2 (ja) 2015-01-22 2021-03-01 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP2022159466A Pending JP2022173519A (ja) 2015-01-22 2022-10-03 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021031635A Active JP7440092B2 (ja) 2015-01-22 2021-03-01 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP2022159466A Pending JP2022173519A (ja) 2015-01-22 2022-10-03 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現

Country Status (13)

Country Link
US (6) US9763896B2 (enExample)
EP (2) EP4306167B1 (enExample)
JP (3) JP6951976B2 (enExample)
KR (1) KR102690198B1 (enExample)
CN (2) CN116617195A (enExample)
AU (2) AU2016209255B2 (enExample)
BR (1) BR112017015721A2 (enExample)
CA (1) CA2974092A1 (enExample)
ES (2) ES2961334T3 (enExample)
HK (1) HK1247101A1 (enExample)
MX (2) MX392410B (enExample)
PT (1) PT3247340T (enExample)
WO (1) WO2016118741A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392410B (es) * 2015-01-22 2025-03-11 Mitochon Pharmaceuticals Inc Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas.
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo
MX2019009038A (es) * 2017-01-31 2019-12-09 L Manfredi Paolo D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US12637411B2 (en) 2019-01-30 2026-05-26 Mggm Llc Structurally modified opioids for prevention and treatment of diseases and conditions
US20230363418A1 (en) * 2020-09-29 2023-11-16 Cefo Co., Ltd. Composition for preventing or treating neuropsychologic disease, comprising manf
WO2023205625A2 (en) * 2022-04-18 2023-10-26 Mitochon Pharmaceuticals, Inc. 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases
WO2025051360A1 (en) * 2023-09-06 2025-03-13 Instituto de Medicina Molecular João Lobo Antunes Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
EP2170338A2 (en) 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
CN110302385A (zh) * 2013-08-30 2019-10-08 耶鲁大学 新型2，4-二硝基苯酚制剂和使用其的方法
MX392410B (es) * 2015-01-22 2025-03-11 Mitochon Pharmaceuticals Inc Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas.

Also Published As

Publication number Publication date
CN116617195A (zh) 2023-08-22
JP2018502898A (ja) 2018-02-01
EP4306167B1 (en) 2025-12-24
MX2022005937A (es) 2022-06-29
PT3247340T (pt) 2023-10-31
US11717497B2 (en) 2023-08-08
AU2016209255B2 (en) 2021-07-01
ES3057870T3 (en) 2026-03-05
EP4306167A3 (en) 2024-03-20
WO2016118741A1 (en) 2016-07-28
US10864173B2 (en) 2020-12-15
US10220006B2 (en) 2019-03-05
US20160213625A1 (en) 2016-07-28
US20210052513A1 (en) 2021-02-25
MX392410B (es) 2025-03-11
JP2021080286A (ja) 2021-05-27
US9763896B2 (en) 2017-09-19
US20190142765A1 (en) 2019-05-16
CA2974092A1 (en) 2016-07-28
EP3247340A1 (en) 2017-11-29
US20170065536A1 (en) 2017-03-09
US20240156750A1 (en) 2024-05-16
JP7440092B2 (ja) 2024-02-28
MX2017009402A (es) 2017-12-04
CN107405315A (zh) 2017-11-28
ES2961334T3 (es) 2024-03-11
KR102690198B1 (ko) 2024-07-30
EP4306167C0 (en) 2025-12-24
EP3247340B1 (en) 2023-08-02
HK1247101A1 (zh) 2018-09-21
US20180125794A1 (en) 2018-05-10
US9974755B2 (en) 2018-05-22
BR112017015721A2 (pt) 2018-04-10
EP4306167A2 (en) 2024-01-17
AU2016209255A1 (en) 2017-08-10
AU2021240120A1 (en) 2021-10-28
KR20170104597A (ko) 2017-09-15
JP2022173519A (ja) 2022-11-18

Similar Documents

Publication Publication Date Title
JP7440092B2 (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
Glassman et al. Potentiation of a monoamine oxidase inhibitor by tryptophan
Sprenger et al. Management of motor and non-motor symptoms in Parkinson’s disease
Raskin et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder
WO2020198039A1 (en) Ketamine for treatment of sensory processing deficits
RS60240B1 (sr) Postupci i kompozicije za lečenje depresije korišćenjem ciklobenzaprina
KR20180034442A (ko) 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
JP7121859B2 (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
HK40106997A (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
Amsterdam et al. Once-versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study
Plioplys et al. Overview of Pediatric Psychopharmacology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210301

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210310

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210513

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210927

R150 Certificate of patent or registration of utility model

Ref document number: 6951976

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250